All In Biotech

Drug Trial Radar · NCT01121536

Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

Last checked: Nov 20, 2026Latest source record: Sep 21, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

867

Actual

Start

Apr 30, 2010

Primary completion

Oct 31, 2013

Study completion Oct 31, 2013

Sponsor

Lead sponsor
CephalonIndustry
Sponsor type
Industry
First posted
May 12, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the safety and tolerability of long term (6 months) armodafinil treatment as adjunctive therapy to mood-stabilizing medications in adults with bipolar I disorder.

Conditions

  • Depression

Interventions

  • ArmodafinilDrug

    Armodafinil tablets, taken orally, once daily in the morning

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Participants With Treatment-Emergent Adverse Events (TEAE)Time frame: Day 1 up to Month 6
  2. Participants With Clinically Significant Abnormal Serum Chemistry ValuesTime frame: Day 1 to Month 6
  3. Participants With Clinically Significant Abnormal Hematology ValuesTime frame: Day 1 to Month 6
  4. Participants With Clinically Significant Abnormal Urinalysis ValuesTime frame: Day 1 to Month 6
  5. Participants With Clinically Significant Abnormal Vital Signs ValuesTime frame: Day 1 to Month 6
  6. Change From Baseline to Endpoint in Electrocardiogram (ECG) ValuesTime frame: Day 0 (baseline), Month 6 or last post-baseline observation
  7. Physical Examination Shifts From Baseline to EndpointTime frame: Day 0 (baseline), Month 6 (or last post-baseline observation)
  8. Change From Baseline to Endpoint in Body WeightTime frame: Day 0 (baseline), Month 6 (or last post-baseline observation)
  9. Change From Baseline to Endpoint in the Young Mania Rating Scale (YMRS) Total ScoreTime frame: Day 0 (baseline), Month 6 or last post-baseline observation
  10. Participants With Findings During the Open-Label Study on the Columbia-Suicide Severity Rating Scale 'Since Last Visit' Version (C-SSRS-SLV)Time frame: Day 1, Week 1, Months 1, 2, 4 and 6 or last post-baseline visit
  11. Change From Baseline to Endpoint in the Insomnia Severity Index (ISI) Total ScoreTime frame: Day 0 (baseline), Month 6 (or last post-baseline observation)
  12. Change From Baseline to Endpoint in the Hamilton Anxiety Scale (HAM-A) Total ScoreTime frame: Day 0 (baseline), Month 6 or last post-baseline observation

Locations

158 sites in 17 countries. Site status is shown where the registry gives one.

  • Teva Investigational Site 113

    Birmingham, Alabama

  • Teva Investigational Site 225

    Birmingham, Alabama

  • Teva Investigational Site 229

    Anaheim, California

  • Teva Investigational Site 217

    Cerritos, California

  • Teva Investigational Site 223

    Cerritos, California

  • Teva Investigational Site 115

    Garden Grove, California

  • Teva Investigational Site 121

    Imperial, California

  • Teva Investigational Site 303

    Oceanside, California

  • Teva Investigational Site 400

    Oceanside, California

  • Teva Investigational Site 200

    Pico Rivera, California

  • Teva Investigational Site 128

    San Diego, California

  • Teva Investigational Site 201

    San Diego, California

  • Teva Investigational Site 192

    Santa Ana, California

  • Teva Investigational Site 292

    Santa Ana, California

  • Teva Investigational Site 295

    Sherman Oaks, California

  • Teva Investigational Site 122

    Temecula, California

  • Teva Investigational Site 131

    Gainesville, Florida

  • Teva Investigational Site 132

    Jacksonville, Florida

  • Teva Investigational Site 606

    Jacksonville Beach, Florida

  • Teva Investigational Site 127

    Lauderhill, Florida

  • Teva Investigational Site 119

    North Miami, Florida

  • Teva Investigational Site 118

    Tampa, Florida

  • Teva Investigational Site 608

    Tampa, Florida

  • Teva Investigational Site 205

    Atlanta, Georgia

  • Teva Investigational Site 116

    Atlanta, Georgia

  • Teva Investigational Site 204

    Smyrna, Georgia

  • Teva Investigational Site 107

    Naperville, Illinois

  • Teva Investigational Site 301

    Naperville, Illinois

  • Teva Investigational Site 219

    Oakbrook Terrace, Illinois

  • Teva Investigational Site 195

    Park Ridge, Illinois

  • Teva Investigational Site 600

    Lafayette, Indiana

  • Teva Investigational Site 300

    Pikesville, Maryland

  • Teva Investigational Site 603

    Watertown, Massachusetts

  • Teva Investigational Site 290

    Flowood, Mississippi

  • Teva Investigational Site 133

    St Louis, Missouri

  • Teva Investigational Site 103

    Mount Laurel, New Jersey

  • Teva Investigational Site 212

    Mount Laurel, New Jersey

  • Teva Investigational Site 193

    Albuquerque, New Mexico

  • Teva Investigational Site 207

    Brooklyn, New York

  • Teva Investigational Site 104

    Brooklyn, New York

Showing 40 of 158 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.